🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

6,931 results for “The” Clear

  1. Cemiplimab

    Regeneron UK Limited

    Pleural Mesotheliomas

    phase 2 small molecule active

    1 trial

  2. Cemiplimab

    Regeneron UK Limited

    Bladder Urothelial Carcinoma

    phase 2 small molecule active

    1 trial

  3. Cenderitide

    CAPRICOR THERAPEUTICS, INC.

    Heart Failure

    phase 2 small molecule completed

    2 trials

  4. Cenegermin, The placebo for investigational lyophilized cenegermin Drug Product is the same as the Drug Product with the exception that it does not contain cenegermin.

    Dompe' Farmaceutici S.p.A.

    Spastic Cerebral Palsy

    phase 2 small molecule active

    1 trial

  5. Ceralasertib

    United Therapeutics Europe Ltd

    Gynaecological Cancers

    phase 2 small molecule active

    1 trial

  6. Cesium-131 brachytherapy

    GT Biopharma

    Recurrent Brain Metastases

    phase 2 other active

    1 trial

  7. Cetuximab

    United Therapeutics Europe Ltd

    BRAF V600E Negative

    phase 2 mab active

    1 trial

  8. ChAdOx1-HBV

    Barinthus Biotherapeutics plc.

    Chronic Hepatitis B

    phase 2 mab completed

    1 trial

  9. ChAdOx1-HBV

    Barinthus Biotherapeutics plc.

    Hepatitis B

    phase 2 mab completed

    2 trials

  10. ChAdOx1-HPV

    Barinthus Biotherapeutics plc.

    HPV Infection

    phase 2 mab completed

    1 trial

  11. ChAdOx1-MVA 5T4 vaccine

    Barinthus Biotherapeutics plc.

    Intermediate Risk Prostate Cancer

    phase 2 mab terminated

    1 trial

  12. ChAdOx1-PCAQ

    Barinthus Biotherapeutics plc.

    Prostate Cancer

    phase 2 mab terminated

    1 trial

  13. Chemotherapy + immunotherapy

    Hunan Province Tumor Hospital

    Non Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  14. Chemotherapy plus apatinib

    Lei Li

    Recurrent Cervical Carcinoma

    phase 2 small molecule completed

    1 trial

  15. Chemotherapy+PD-1 inhibitor+8Gy x 3f

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    HR+HER2- Breast Cancer

    phase 2 small molecule active

    1 trial

  16. Chidamide

    The First People's Hospital of Lianyungang

    Neuroendocrine Tumors

    phase 2 small molecule active

    2 trials

  17. Chidamide + Tislelizumab + chemotherapy (CapeOX )

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Colon Adenocarcinoma

    phase 2 small molecule active

    1 trial

  18. Chidamide Combined with NKG2D CAR-NK Cell Therapy

    The First People's Hospital of Lianyungang

    HIV (Human Immunodeficiency Virus)

    phase 2 small molecule active

    1 trial

  19. Chidamide combined with Duvillisib

    The First People's Hospital of Lianyungang

    Peripheral T Cell Lymphoma

    phase 2 small molecule active

    1 trial

  20. Chinese herbal therapy

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Urinary Incontinence, Stress

    phase 2 other completed

    1 trial

  21. Choice Of the Most Active Strategies for Short term recurring Triple Negative Breast Cancer A phase Ib/II, open-label, modular, dose-finding and dose-expansion study to explore safety, tolerability, pharmacokinetics, and anti-tumor activity of novel therapeutics in patients with early relapsed metastatic triple-negative breast cancer

    The George Institute

    Patients with hormone-receptor negative and HER2-negative (IHC 0, 1+ or IHC 2+/ISH-) breast cancer with early relapse while on (neo) adjuvant systemic treatment or within 12 months from the end of all treatments with curative intent.

    phase 2 other active

    1 trial

  22. Ciclosporin

    United Therapeutics Europe Ltd

    Myocardial Reperfusion Injury

    phase 2 small molecule completed

    1 trial

  23. Ciprofloxacin

    United Therapeutics Europe Ltd

    Crohn's Disease

    phase 2 small molecule completed

    1 trial

  24. Cisplatin

    Ultragenyx UK Limited

    Squamous Cell Carcinoma of the Anus

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources